

## Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweertorial #3 References

### Tweet 5

ENHERTU® (fam-trastuzumab deruxtecan-nxki) [prescribing information]. Daiichi Sankyo, Inc. Approved 2019. Revised January 2021.

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/761139s011lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Esophageal and Esophagogastric Cancers (v4.2021). Updated August 3, 2021. Accessed September 8, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf)

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Gastric Cancer (v5.2021). Updated October 6, 2021. Accessed October 15, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf)

### Tweet 6

Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. *N Engl J Med*. 2020;382(25):2419-2430. doi:10.1056/NEJMoa2004413

### Tweet 7

Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. *Future Oncol*. 2021;17(10):1155-1164. doi:10.2217/fon-2020-1007

ClinicalTrials.gov. Combination margetuximab, INCMGA00012, MGD013, and chemotherapy phase 2/3 trial in HER2+ gastric/GEJ cancer (MAHOGANY). NCT04082364. Updated November 8, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04082364>

ClinicalTrials.gov. Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). NCT04704934. Updated September 10, 2021. Accessed November 10, 2021. <https://clinicaltrials.gov/ct2/show/NCT04704934>

ClinicalTrials.gov. Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer (MOUNTAINEER-02). NCT04499924. Updated October 5, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04499924>

### Tweet 8

ClinicalTrials.gov. Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). NCT04704934. Updated September 10, 2021. Accessed November 10, 2021. <https://clinicaltrials.gov/ct2/show/NCT04704934>

Shitara K, Seraj J, Franke FA, et al. 1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study. *Ann Oncol*. 2021;32:S1073. doi:10.1016/j.annonc.2021.08.1545

#### **Tweet 9**

ClinicalTrials.gov. Tucatinib, trastuzumab, ramucirumab, and paclitaxel versus paclitaxel and ramucirumab in previously treated HER2+ gastroesophageal cancer (MOUNTAINEER-02). NCT04499924. Updated October 5, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04499924>

Strickler JH, Nakamura Y, Yoshino T, et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—trial in progress. *J Clin Oncol*. 2021;39(3\_suppl):TPS252-TPS252. doi:10.1200/JCO.2021.39.3\_suppl.TPS252

#### **Tweet 11**

Catenacci DV, Rosales M, Chung HC, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. *Future Oncol*. 2021;17(10):1155-1164. doi:10.2217/fon-2020-1007

ClinicalTrials.gov. Combination margetuximab, INCMGA00012, MGD013, and chemotherapy phase 2/3 trial in HER2+ gastric/GEJ cancer (MAHOGANY). NCT04082364. Updated November 8, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT04082364>

## Glossary

ADC, antibody-drug conjugate  
AE, adverse event  
chemo, chemotherapy  
CI, confidence interval  
CNS, central nervous system  
DCR, disease control rate  
DOR, duration of response  
FC, fragment crystallizable  
GEC, gastroesophageal junction adenocarcinoma  
GC, gastric cancer  
HER2, human epidermal growth factor receptor 2  
HR, hazard ratio  
IgG1, immunoglobulin G1  
IO, immunotherapy  
LA, locally advanced  
LAG-3, lymphocyte activation gene 3  
MOA, mechanism of action  
mOS, median overall survival  
mPFS, median progression-free survival  
ORR, objective response rate  
OS, overall survival  
PD-1, programmed cell death receptor 1  
PFS, progression-free survival  
Ph, phase  
QOL, quality of life  
T-DXd, trastuzumab deruxtecan  
w/, with